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Background: As it is unknown whether complete asthma remission or progression of asthma is
associated with airway inflammation and remodeling, we assessed these characteristics in
bronchial biopsies of relevant subsets of asthma patients.
Methods: Sputum and bronchial biopsies were obtained from asthma patients in remission (PC20
histamine> 32 mg/ml, PC20 AMP> 320 mg/ml) and from those with either a slow FEV1 decline
(<30 ml/year) or fast decline (>30 ml/year). Inflammatory cells andmediatorswere determined
in sputum, inflammatory cells and aspects of airway remodeling in bronchial biopsies.
Results: Asthmatics in remission and asthma patients with a slow FEV1 decline had a similar
extent of airway inflammation and remodeling in sputumandbronchial biopsies. Asthmapatients
with a fast FEV1 decline had high sputum eosinophil numbers. Moreover, FEV1 decline (ml/year)
correlated with sputum eosinophil numbers (RsZ 0.51, pZ 0.003) and ECP levels (RsZ 0.57,
pZ 0.001). Airway remodeling, i.e. basement membrane thickness, correlated with sputum
eosinophils (RsZ 0.69, p< 0.001), sputumECP (RsZ 0.46, pZ 0.018) andairwaywall eosinophil
numbers (RsZ 0.49, pZ 0.002).
Conclusions: Asthma, evenwhen in remission, is accompaniedby airway inflammation and remo-
deling. Data suggest that eosinophils are important in a subset of asthma patients by association
to accelerated FEV1 decline and change of basement membrane thickness.
ª 2010 Elsevier Ltd. All rights reserved.) 50 3613532; fax: þ31 (0) 50 3619320.
int.umcg.nl (N.H.T. ten Hacken).
0 Elsevier Ltd. All rights reserved.
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Asthma is a chronic inflammatory disorder of the airways
associated with airway obstruction that is often reversible,
either spontaneously or with treatment. Nevertheless,
asthma patients have on average a lower lung function than
healthy controls.1 Furthermore, some patients have an
even accelerated decline in forced expiratory volume in 1 s
(FEV1) over time,
2 probably caused by ongoing airway
inflammation and the resulting airway remodeling.3 Not all
asthmatics are predestined for this scenario since some
subjects show stable lung function and others even outgrow
their disease. As yet, it is unknown whether these differ-
ences in the natural course of clinical asthma reflect
differences in the underlying inflammatory processes and
structural changes in the airways.
Some patients fully outgrow their asthma, so-called
asthma remission, which is characterized by normal lung
function, absence of bronchial hyperresponsiveness (BHR)
and respiratory symptoms while not using asthma medica-
tion.4 Others are in “clinical” asthma remission, i.e. they
are asymptomatic but still show BHR. The latter type of
remission is associated with ongoing airway inflammation
and remodeling as reflected by increased numbers of
eosinophils, T-cells and mast cells in the airway mucosa and
thickening of the reticular basement membrane (BM) when
compared to control subjects without asthma.5 However, it
is unknown whether complete remission with the absence
of BHR is associated with less airway inflammation and
remodeling when compared to persistent asthma. There-
fore, we investigated airway inflammation and remodeling
in patients with complete asthma remission, defined by the
absence of BHR, asthma symptoms and treatment.
Previous studies have revealed multiple risk factors for
an accelerated FEV1 decline (15e50 ml/year) in asthma:
low baseline lung function (FEV1 % predicted),
6 less
reversibility to b2-agonists,6 more severe BHR,7 smoking,8
increased mucus production,2 male gender9 and frequent
exacerbations.10 The pathological processes underlying the
accelerated FEV1 decline in asthma are unknown. Several
suggestions for the underlying pathological process come
from cross-sectional studies demonstrating an association
between the above described risk factors and markers of
airway inflammation and remodeling. For example, low
baseline lung function has been associated with increased
airway wall thickness,11 more severe BHR with thickening of
the subepithelial BM,12 smoking with epithelial meta-
plasia,13 goblet cell hyperplasia14 and increased sub-
epithelial collagen deposition,15 and increased mucus
production has been associated with hyperplasia and
hypertrophy of epithelial goblet cells16 and increased
presence of submucosal mucous glands.16 Moreover, Ulrik
et al.17 showed an association between higher blood
eosinophil numbers and accelerated FEV1 decline in adult
asthma patients, thereby postulating a role of eosinophils.
Based on these findings it is tempting to speculate that an
accelerated FEV1 decline in asthma indeed results from
progressive airway inflammation and remodeling.
Aim of this study was to characterize the pathological
background of asthma remission and progression. There-
fore, we recruited 47 steroid-naı¨ve, non-smoking subjectswith a documented asthma diagnosis in the past, we
assessed their annual FEV1 decline over a minimum period
of at least 5 years and categorized them into 3 groups:
subjects with asthma remission, current asthma patients
with a slow FEV1 decline (<30 ml/year) and a fast FEV1
decline (>30 ml/year). Airway inflammation and remodel-
ing were investigated in sputum samples and bronchial
biopsies.
Methods
Subjects
Non-smoking subjects (nZ 47) aged between 32 and 70
years, without oral or inhaled corticosteroids were
recruited. All subjects originated from research cohorts
investigated earlier by our research group and all had
a doctor’s diagnosis of asthma and a documented PC20
histamine (using 30-s tidal breathing) 32 mg/ml in the
past.4 These subjects were extensively characterized
according to a standard protocol (including FEV1) at least
five years prior to our study. Subjects were re-assessed in
the present study with lung function, hyperresponsiveness
to adenosine 50-monophosphate (AMP), sputum induction
and bronchial biopsies. Three groups were identified: 1)
asthma remission (FEV1> 90% predicted, PC20
AMP> 320 mg/ml, PC20 histamine> 32 mg/ml), 2) slow
FEV1 decline (<30 ml/year over at least 5 years and PC20
AMP 320 mg/ml or PC20 histamine 32 mg/ml), 3) fast
FEV1 decline (>30 ml/year over at least 5 years and PC20
AMP 320 mg/ml or PC20 histamine 32 mg/ml). Main
exclusion criteria were: the use of corticosteroids during
the period over which the FEV1 decline was being calcu-
lated or more than 5 years of cumulative corticosteroid use
in the distant past. Furthermore, FEV1< 1.2 l, bronchiec-
tases, upper respiratory tract infection (e.g. colds) and/or
use of antibiotics the last 2 months before inclusion were
exclusion criteria. The study protocol was approved by the
local medical ethics committee. All subjects gave their
written informed consent.
Study design
Peripheral blood eosinophil counts and IgE, induced sputum
samples and lung function (flow-volume, CO diffusion) were
obtained. An AMP provocation test was performed followed
1e2 weeks later by a bronchoscopy. Subjects with a nega-
tive AMP provocation test (PC20 AMP> 320 mg/ml) were
subjected to a histamine provocation test >3 weeks later to
determine BHR.
Lung function
FEV1 was measured with a calibrated water-sealed
spirometer at the current and past visit (Lode Spirograph
D53, Lode Instruments, Groningen, the Netherlands).
Reversibility of FEV1 (% predicted) was measured after
administration of 800 mg of Albuterol. Annual FEV1 decline
(ml/year) was calculated by subtracting FEV1 (post-bron-
chodilator) at the first and second measurement, divided by
1256 M. Broekema et al.the number of years between the two measurements
(minimum of 5 years). Provocation tests were performed
with a method adapted from Cockcroft and coworkers.18
After an initial nebulized 0.9% saline challenge, subjects
inhaled doubling concentrations AMP (0.04e320 mg/ml) by
2-min tidal breathing, at 5-min intervals. BHR to histamine
was tested as reported previously,19 using 30-s tidal
breathing and doubling concentrations ranging from 0.13 to
32 mg/ml.
Atopy measurements
Atopy was determined by the Phadiatop screening test with
the ImmunoCap system (Phadia AB, Sweden) and results are
presented as quotients (fluorescence of the serum of
interest divided by the fluorescence of a control serum).
Positive Phadiatop was defined as patient serum/control
serum> 1.
Sputum induction and processing
Sputum was induced by inhalation of 5% hypertonic saline
aerosols as over 3 consecutive periods of 5 min. Processed
whole sputum samples were stained with May Gru¨nwald
Giemsa (MGG) to obtain cell differentials by counting total
600 viable, non-squamous cells. Sputum was not scored if
the percentage squamous cells was >80% or the total
number of non-squamous cells was <600.
Sputum supernatant measurements
Histamine was measured by ELISA (IBL, Hamburg,
Germany). Adenosine was measured by HPLC as described
previously.20 The concentration of eosinophilic cationic
protein (ECP) was measured using a fluoroenzyme immu-
noassay (ImmunoCAP ECP, Pharmacia, Uppsala, Sweden).
Secreted mucin was measured by double-sandwich ELISA
(Covance, Emeryville, USA), with the 17B1 protein-G puri-
fied antibody and 17Q2 alkaline phosphatase-conjugated
antibody specifically binding to the granules of the surface
goblet cells and mucous gland cells, as previously
described.21
Collection, processing and immunohistochemical
staining of bronchial biopsies
After local anaesthesia, bronchial biopsies were obtained
using a flexible bronchoscope (type Olympus BF P20 or BF
XT20) from segmental divisions of the main bronchi. The
biopsies were fixed in 4% formalin, processed and
embedded in paraffin. Bronchial biopsies were cut in 3 mm
thick sections. All stainings were performed in an auto-
mated system using the DAKO autostainer and were
manually counterstained with methylgreen.
The inflammatory profile was assessed with specific
antibodies against eosinophilic peroxidase (EPX, the labo-
ratories of Drs. NA Lee and JJ Lee), mast cell tryptase (AA1,
DAKO, Glostrup, Denmark), macrophages (CD68, DAKO),
neutrophil elastase (NP57, DAKO) and T-lymphocytes (CD3
(DAKO), CD4 (Novocastra, Newcastle upon Tyne, UK) and
CD8 (DAKO)). In short, sections were deparaffinized andafter antigen retrieval, incubated with the primary anti-
bodies. These antibodies were detected with Envision
Detection Kit (DAKO) except for EPX and CD8, which were
detected using biotinylated anti-mouse IgG1 (Southern
Biotechnology, Birmingham, AL, USA) and alkaline phos-
phatase- (DAKO) or peroxidase-labelled streptavidine
conjugates (DAKO). Permanent Red (DAKO) or NovaRED
(Vector Labs, Burlingame, USA) was used as chromogen.
Periodic acid-Schiff (PAS) staining was used to determine
the presence of goblet cells in the bronchial epithelium.
Haematoxylin eosin (HE) staining was used for evaluation of
epithelial integrity and basement membrane (BM)
thickness.
Deposition of extracellular matrix (ECM) components in
the subepithelial compartment was assessed by specific
antibodies against collagen 3 (Southern Biotechnology),
decorin (dermatan sulfate proteoglycan, Seikagaku, Tokyo,
Japan) and versican (large proteoglycan (versican), Seika-
gaku). In short, sections were deparaffinized and after
antigen retrieval, incubated with the primary antibodies.
These antibodies were detected with Envision Detection
Kit (DAKO) except for collagen 3, which was detected using
peroxidase-labelled rabbit anti-goat and goat anti-rabbit
conjugates (both DAKO). 3.30-Diaminobenzidine tetrachlo-
ride (DAKO) was used as chromogen.Quantification of the histological stainings
Quantification of inflammatory cells was performed using
computerized-assisted image analysis at a magnification of
200 (Qwin, Leica Microsystems Imaging Solutions, Cam-
bridge, UK). A blinded investigator counted the number of
positively stained inflammatory cells in the submucosal
area. This submucosal area was restricted to 100 mm under
the basement membrane (BM) and a total area of 0.1 mm2.
For each subject three sections of one biopsy sample were
counted (totally 0.3 mm2 tissue) and average numbers were
used for further analysis.
The number of goblet cells was counted on PAS-stained
biopsy sections, in layers with intact epithelium, and
expressed per mm of BM. Epithelial integrity was deter-
mined using HE-stained biopsy sections and was expressed
as the percentage of BM that was covered with either intact
epithelium (a layer of basal and ciliated columnar epithelial
cells without detachment from the BM), only basal
epithelial cells, metaplastic epithelium (multilayered
epithelium covered by a flattened layer of squamous
epithelial cells and absence of ciliated cells) or the
percentage of BM that was denuded from epithelial cells.
BM thickness was determined by the measurement of the
total BM length and surface on HE-stained biopsy sections.
Tangentially cut sections were excluded. Subsequently, the
mean thickness could be calculated by dividing the BM
surface area by its length.
Expression of ECM components was measured by deter-
mining the colour threshold of stained tissue, using
computerized-assisted image analysis. The percentage of
positive tissue per biopsy section was determined in the
submucosal area 200 mm under the BM. For each subject
two different biopsy sections were quantified and average
percentages were used for further analysis.
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All analyses were performed using SPSS (version 14.0; SPSS
Inc, Chicago, IL, USA). Normality of distributions was
assessed using the KolmogoroveSmirnov test. When neces-
sary, normalization by transformation was attempted. Nor-
mally distributed data was analysed with one-way ANOVA
and independent samples t-tests. Non-normally distributed
data was analysed with KruskaleWallis and ManneWhitney U
tests. Chi-square tests were used to compare groups for
dichotomous variables. Correlations were evaluated by
Pearson (for normally distributeddata) or Spearman (for non-
normally distributed data) tests. Two tailed p-values of
<0.05 were considered statistically significant.
Results
Subject characteristics
Forty-seven subjects were included: 10 subjects with
complete asthma remission, 20 asthma patients with a slow
FEV1 decline over at least 5 years (<30 ml/year) and 17
with a fast FEV1 decline over at least 5 years (>30 ml/year).
As expected, FEV1 was lowest in asthmatics with a fast FEV1
decline, intermediate with a slow decline and highest in
asthma remission; reversibility was not significantly
different between the three groups. Asthma patients with
a fast FEV1 decline had significantly higher blood eosinophil
counts than those with a slow FEV1 decline (Table 1).
Inflammatory cells and inflammatory mediators in
sputum
The absolute number of sputum eosinophils was higher in
patients with a fast FEV1 decline than with a slow FEV1
decline (Table 2, Fig. 1A). Annual FEV1 decline correlatedTable 1 Patient characteristics.
Remission (nZ 1
Sex (M/F) 3/7
Age (yr) 53 (32e67)
FEV1 decline (ml/year) 8.0 (35e35)
Interval between FEV1 measurements (years) 8.7 (6e14)
FEV1 (% predicted) 111 (102e146)
FEV1/VC (%) 79 (67e93)
MEF50 (% predicted) 105 (60e147)
Reversibility FEV1 (%) 3.9 (0.4e11.5)
PC20AMP (mg/ml) >320
KCO (% predicted) 95 (84e131)
IgE (IU/L) 60 (7e231)
Positive Phadiatop (n (%)) 5 (50%)
Phadiatop score (ratio) 0.96 (0.33e54)
Blood eosinophils (109/l) 0.12 (0.06e0.24)
Values are presented as median values (ranges), unless stated otherwis
of Albuterol; reversibility FEV1Z change in FEV1, expressed as increa
AMPZ provocative concentration of adenosine 50 monophoshate causi
serum/control serum >1; nZ number. *p< 0.05 remission vs. slow FEV
vs. fast FEV1 decline.significantly with the absolute number of sputum eosino-
phils (Fig. 1B). Sputum neutrophils, macrophages and
lymphocytes did not significantly differ between the three
study groups (Table 2).
The levels of inflammatory mediators in the supernatant
of induced sputum, i.e. histamine, adenosine and mucin
were similar for subjects with asthma remission and asthma
patients with a slow or a fast FEV1 decline (Table 2).
Moreover, the levels of inflammatory cytokines and growth
factors (IFN-g, IL-4, 5, 8, 13, 17, EGF, Eotaxin, FGFb, GM-
CSF, MCP1, RANTES, VEGF) were similar for all groups
(See additional file 1). Sputum ECP values were highest in
asthma patients with a fast FEV1 decline (59.8 (12e2467)
mg/l), values being significantly higher than in subjects with
asthma remission (16.0 (3e172) mg/l) and slightly, but not
significantly, higher than in asthma patients with a slow
FEV1 decline (27.0 (6e447) mg/l, pZ 0.056) (Table 2,
Fig. 1C). Moreover, a higher annual FEV1 decline correlated
significantly with higher sputum ECP levels (Fig. 1D).
Inflammatory cells in bronchial biopsies
No significant differences were observed in numbers of
eosinophils, mast cells, macrophages, neutrophils and T-
lymphocytes in bronchial biopsies of subjects with asthma
remission, asthma patients with a slow or fast FEV1 decline
(Table 3, Fig. 2AeC).
Airway remodeling determined in bronchial
biopsies
No differences were observed in remodeling parameters in
bronchial epithelium (goblet cells and epithelial integrity),
BM (thickness) and submucosal tissue (presence of ECM
components) between subjects with asthma remission and
asthma patients with a slow or fast FEV1 decline (Table 4).0) Slow FEV1 decline (nZ 20) Fast FEV1 decline (nZ 17)
11/9 12/5
48 (35e70) 53 (38e64)
18.6 (27e29) 50.3 (34e105)#,$
8.9 (5e13) 9.3 (5e13)
100 (78e131)* 98 (77e127)#
75 (65e91) 73 (56e84)#
69 (46e147)* 68 (36e98)#
8 (0.4e28.7) 8.3 (8.4e17.2)
>320 (0.02 to >320)* 46.2 (0.02 to >320)#
99 (78e127) 110 (82e141)
66 (14e552) 70 (11e558)
13 (65%) 13 (76%)
9.1 (0.22e92) 15 (0.06e92)
0.12 (0.02e0.35) 0.19 (0.07e0.51)$
e. All spirometric data were determined after inhalation of 800 mg
se in percentage predicted value after 800 mg of Albuterol; PC20
ng a 20% fall in FEV1; Positive PhadiatopZ specific IgE’s in patient
1 decline,
#p< 0.05 remission vs. fast FEV1 decline,
$p< 0.05 slow
Table 2 Inflammatory cells and mediators in sputum.
Remission (nZ 10) Slow FEV1 decline (nZ 20) Fast FEV1 decline (nZ 17)
No sputum 2 (20%) 3 (15%) 3 (18%)
Sputum not evaluable
>80% squamous n (%) 1 (10%) 2 (10%) 3 (18%)
<600 cells n (%) e e 2 (11%)
Total cells (106/ml) 0.46 (0.06e2.90) 0.31 (0.12e2.27) 0.41 (0.03e2.05)
Neutrophils (%) (106/ml) 62 (19e78) 60 (20e94) 55 (35e85)
0.40 (0.03e1.19) 0.21 (0.03e1.58) 0.28 (0.11e1.44)
Macrophages (%) (106/ml) 36 (20e78) 32 (5e76) 33 (13e62)
0.16 (0.02e2.14) 0.10 (0.01e1.07) 0.18 (0.08e0.61)
Eosinophils (%) (106/ml) 0.2 (0e4.6) 0.2 (0e4.8) 1.8 (0e26.0)
0.002 (0e0.03) 0.001 (0e0.02) 0.01 (0e0.34)*
Lymphocytes (%) (106/ml) 2.2 (1.4e7.3) 2.6 (0.2e6.9) 1.3 (0e5.6)
0.02 (0.001e0.04) 0.01 (0.001e0.07) 0.004 (0e0.11)
Histamine (ng/ml) 13.4 (2.8e29.8) 9.1 (0.2e28.8) 13.8 (4.8e38.0)
Adenosine (ng/ml) 56.5 (8.0e110) 34.6 (6.2e178) 23.0 (0.9e201)
ECP (mg/l) 16.0 (2.5e172) 27.0 (6.0e447) 59.8 (11.9e2467)*,#
Mucin (units) 0.25 (0.04e3.9) 0.78 (0.08e10.3) 1.0 (0.18e2.7)
Values are presented as median values (percentages or ranges). Eosinophils: *p< 0.05 vs. slow FEV1 decline. ECP: *pZ 0.056 vs. slow
FEV1 decline,
#p< 0.05 vs. remission. For luminex data see Table S1.
1258 M. Broekema et al.BM thickness correlated significantly with all investi-
gated parameters in sputum and bronchial biopsies that are
associated with eosinophilic inflammation, i.e. sputum
eosinophils (Fig. 3A), sputum ECP (Fig. 3B) and EPXþ cells in
biopsies (Fig. 3C). The correlation scatters showed two
outliers for BM thickness (Fig. 3). However, without these
two subjects, significant correlations were still presentFigure 1 Eosinophilic inflammation in sputum. (A) Absolute num
asthma remission and asthmatic subjects with a slow or a fast FEV1
the absolute number of sputum eosinophils (log transformed). (C) S
and asthmatic subjects with a slow or a fast FEV1 decline. (D) Corr
transformed). Each closed circle represents one subject. Horizontabetween BM thickness and all investigated eosinophil
markers (not shown).
Discussion
The present study describes the pathological background of
asthma remission and progression in a well-characterizedber of sputum eosinophils (log transformed) in subjects with
decline. (B) Correlation between the annual FEV1 decline and
putum ECP (log transformed) in subjects with asthma remission
elation between the annual FEV1 decline and sputum ECP (log
l bars represent median values.
Table 3 Inflammatory cells in bronchial biopsies.
Remission (nZ 9) Slow FEV1 decline (nZ 18) Fast FEV1 decline (nZ 11)
EPXþ eosinophils 4 (0e10) 3 (0e18) 3 (0e40)
AA1þ mast cells 5 (1e20) 3 (0e13) 7 (1e19)
CD68þ macrophages 17 (12e86) 16 (4e37) 17 (3e30)
NP57þ neutrophils 9 (2e30) 9 (1e46) 9 (2e38)
CD3þ lymphocytes 75 (35e291) 77 (21e177) 62 (33e246)
CD4þ lymphocytes 19 (9e168) 21 (2e67) 24 (9e65)
CD8þ lymphocytes 28 (7e112) 21 (1e112) 17 (3e103)
Number of cells expressed per 0.1 mm2. Values are presented as median values (ranges). No significant differences between the 3
groups.
Eosinophils in asthma remission and progression 1259group of asthma patients. We investigated patients with
complete asthma remission, i.e. individuals with estab-
lished asthma in the past who at the present time of
investigation lacked asthma symptoms, airway obstruction
and bronchial hyperresponsiveness (BHR) while not using
any asthma treatment. This remission was associated with
a similar extent of inflammation and remodeling as present
in individuals with current asthma and an FEV1 decline in
the range of the normal population. In contrast, patients
with current asthma and a fast FEV1 decline had more
pronounced eosinophilic inflammation in blood and sputum.
In line with this observation, the annual FEV1 decline
correlated significantly with eosinophilia in sputum. Base-
ment membrane (BM) thickness, which is considered as an
important hallmark of airway remodeling, was positively
correlated with eosinophilic inflammation in both sputum
and the airway wall.
An important finding of our study is that these patients
with complete asthma remission have signs of airway wall
inflammation and remodeling. To our surprise, the extent
of airway inflammation and remodeling is compatible with
that of asthma patients with a slow FEV1 decline. The
question remains how to explain the similar findings in
these two different groups of asthma patients. One possible
explanation is that the clinical disease activity is not
determined by the number but rather the activation state
of inflammatory cells, and that complete asthma remission
does not excludes the presence of quiescent inflammatory
cells. However, our data shows that sputum levels of
inflammatory cytokines and growth factors were similar in
subjects with remission and current asthma, suggesting
that the activation status and functionality of theFigure 2 EPXþ eosinophils in bronchial biopsies. Representative p
remission and asthmatic patients with a (B) slow FEV1 decline or ainflammatory cells is not different. Another explanation
may be that clinical disease activity is determined by
inflammation and/or remodeling in other regions of the
lung not accessible by induced sputum or bronchial biop-
sies. The type of clinical expression may for example be
caused by the volume of smooth muscle in more distal parts
of the central or peripheral airways, or the presence or
absence of activated mast cells between smooth muscle
bundles.
Our findings extend observations in other studies since
ongoing airway inflammation and remodeling were also
reported in subjects with less strict criteria for asthma
remission,5,22 i.e. with BHR still present. It is still possible
that these types of asthma patients need anti-inflammatory
treatment. This is an intriguing yet unresolved question
since no study has prospectively followed these patients to
older age.
Our second interesting observation is that an acceler-
ated FEV1 decline is associated with increased sputum
eosinophil numbers and ECP concentrations. This finding
extends results of several cross-sectional studies demon-
strating the relationship between eosinophilic inflammation
and airway obstruction in asthma23,24 and a longitudinal
study showing a positive association between blood eosin-
ophils and FEV1 decline in asthma.
17 However, FEV1 decline
in our asthma patients was not associated with the number
of airway wall eosinophils, just as van Rensen et al.25
found. There are two possible explanations for this
discrepancy. First, bronchial biopsies give only a snap-shot
of the cellular composition of the airway wall which is not
identical to the traffic of inflammatory cells through the
airway wall. Second, an accelerated FEV1 decline may beictures of EPXþ eosinophils in biopsies of subjects in (A) asthma
(C) fast FEV1 decline. Lens magnification 400.
Table 4 Remodeling in bronchial biopsies.
Remission (nZ 9) Slow FEV1 decline (nZ 18) Fast FEV1 decline (nZ 11)
Epithelium Goblet cells (N) 28 (0e42) 36 (7e78) 22 (4e220)
Intact epithelium (%) 6.8 (0e32) 6.8 (0e30) 6.7 (0e34)
Basal epithelium (%) 63 (30e82) 59 (21e100) 50 (13e86)
Denuded BM (%) 22 (0e48) 8 (0e52) 13 (0e59)
Metaplasia (%) 0 (0e21) 0 (0e26) 0 (0e19)
Basement membrane BM thickness (mm) 6.3 (4.9e8.4) 6.6 (3.8e8.6) 7 (4.4e12.6)
Submucosa Versican (%) 45 (20e67) 38 (19e70) 44 (29e69)
Collagen 3 (%) 39 (15e48) 36 (17e63) 40 (9e65)
Decorin (%) 43 (16e76) 36 (15e85) 44 (27e55)
Values are presented as median values (ranges). Intact and basal epithelium, denuded basement membrane (BM) and metaplasia are
presented as the percentage of BM covered with this type of epithelium. Versican, collagen 3 and decorin are presented as the
percentage of positive tissue. No significant differences between the 3 groups.
1260 M. Broekema et al.associated with increased recruitment of eosinophils from
the bone marrow to the blood. Possibly, these eosinophils
move straight from the blood to the luminal space of the
lung and are not retained in the airway wall e.g. due to
epithelial damage.
Although not demonstrated by our study, it can be
anticipated that additional aspects of inflammation,
besides eosinophils, contribute to the FEV1 decline in
asthma as well. Previous studies already have shown an
association between lower FEV1 levels and neutrophilic
inflammation in sputum26 and between accelerated FEV1
decline and CD8-positive T-cells in bronchial biopsies.25
However, these studies did, in contrast to the “clean pop-
ulation” in our study, include asthma patients who smokedFigure 3 Eosinophilic inflammation and basement membrane t
thickness and the absolute number of sputum eosinophils (log trans
(log transformed). (C) Correlation between BM thickness and the
closed circle represents one subject.and/or used ICS, and it is known that smoking and ICS use
change the inflammatory profile.19,27
Our study did not find significant associations between
FEV1 decline and different remodeling parameters like
mucus secretion in sputum and goblet cells in bronchial
epithelium. Lange et al. reported an association between
self-reported mucus production and FEV1 decline.
2 The fact
that the latter study was a large epidemiological study over
many years including a heterogeneous group of smoking and
non-smoking asthmatics may explain the difference with
our study.
Thickening of the subepithelial BM as a result of ECM
deposition is one of the hallmarks of airway remodeling28
and was previously shown to be negatively correlatedhickness. (A) Correlation between basement membrane (BM)
formed). (B) Correlation between BM thickness and sputum ECP
number of EPXþ cells in 0.1 mm2 bronchial biopsy tissue. Each
Eosinophils in asthma remission and progression 1261with the level of FEV1 in asthma.
29 We did not observe an
association between BM thickness and the annual FEV1
decline, which is in line with observations by van Rensen
et al.25 It has to be realized that BM thickening in asthma is
considered to constitute an early airway wall change,
already observed in childhood asthma.30 This may possibly
explain why we did not observe an association with FEV1
decline over the last years. Considering the limited thick-
ening of the BM, mainly in main bronchi, and all functional
studies until now, we think it is less likely that BM thick-
ening contributes to airway dynamics.
Importantly, BM thickness correlated significantly with
sputum eosinophils, ECP concentrations in sputum and
eosinophils in bronchial biopsies, but not with FEV1. Indeed
airway eosinophils have been shown to produce TGF-b31
whereas ECP stimulates secretion of TGF-b by human lung
fibroblasts.32 TGF-b is a well-established inducer of ECM
production by stimulating the proliferation and differenti-
ation of ECM producing cells, i.e. (myo)fibroblasts.33 This
can lead to excessive ECM deposition at the lamina retic-
ularis and thus thickening of the airway subepithelial BM. So
far it is unclear whether thickening of the BM is an
epiphenomenon or really contributes to the accelerated
FEV1 decline.
We realize that our study has both strengths and weak-
nesses. A strength is that we defined asthma remission by
the additional criterion of the absence of BHR for both AMP
and histamine. Thus our definition of asthma remission is
more strict than the classical description of asthma remis-
sion,5,22 and it is better distinguishable from current
asthma. Another strength is that we carefully excluded
subjects with a history of smoking and use of (oral or)
inhaled corticosteroids since ICS are known to reduce27 and
smoking to accelerate FEV1 decline in asthma.
19 The
consequence of this exclusion may be that we included less
severe asthma patients, thereby underestimating the
differences in inflammation and remodeling. However, the
obvious advantage of this exclusion is that our population
enabled us to study the natural course of clinical asthma
without these important confounding factors. A relative
weakness of our study is that, although we studied FEV1
longitudinally in our patients, we only sampled sputum and
bronchial biopsies at the end of follow-up. Therefore, we
cannot exclude the possibility that eosinophilic inflamma-
tion in sputum is not the cause but rather the consequence
of accelerated FEV1 decline. Second, it can be argued that
for an accurate estimation of longitudinal decline in lung
function, two measurements, with an average interval of
8.9 years, are not sufficient.34 However, we would like to
emphasize that the two spirometric measurements in our
study were performed according to a standardized protocol
using the same equipment.
The present study is of clinical relevance since it
suggests the need for specific adaptations in therapy in
subsets of asthma patients. First, we showed that subjects
with complete asthma remission have airway inflammation.
This observation does not support but also not refutes the
recommendation to stop the use of ICS in these subjects.
Long-term studies may give a definite answer on the
question whether airway inflammation ultimately disap-
pears completely. Second, we showed that asthma patients
with a fast FEV1 decline are characterized by increasedeosinophilic inflammation in blood and sputum. Therefore,
intensive ICS treatment, known to reduce the accelerated
FEV1 decline,
27 might be especially beneficial for asth-
matics with increased eosinophilic inflammation. Unfortu-
nately, a subset of asthmatics with increased eosinophilic
inflammation does not respond to intensive ICS treatment,
e.g. due to cigarette smoking, concomitant neutrophilic
inflammation, or small airways involvement. In this specific
subset of asthmatics other measures and medicaments
should be considered.
In conclusion, complete clinical and functional asthma
remission is accompanied by airway inflammation and
remodeling. This indicates that there is no strong rela-
tionship between airway inflammation and BHR and, more
importantly, that asthma remission never is really
“complete”. Furthermore, eosinophilic inflammation may
be important in a subset of asthma patients as eosinophils
are associated with accelerated FEV1 decline and increased
BM thickness.
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